H.U. Group’s Fujirebio Launches Fully Automated pTau217 CSF Assay for Alzheimer’s Research

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automat...

January 30, 2026 | Friday | News
Elevar Submits NDA for Lirafugratinib as Second-Line FGFR2-Driven Cholangiocarcinoma Therapy

  Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating tre...

January 30, 2026 | Friday | News
Ernexa Therapeutics Selected for Japan Entry Acceleration Program, Joining Elite Group of Global Cell Therapy Innovators

Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...

January 29, 2026 | Thursday | News
Propanc Biopharma Files Fourth Provisional Patent in Two Months, Accelerating Global IP Expansion for Lead Cancer Asset

Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel trea...

January 29, 2026 | Thursday | News
SK Capital to Divest Noramco API Assets to Siegfried as Halo Pharma Emerges as Stand-Alone Drug Product CDMO

SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The...

January 29, 2026 | Thursday | News
Boehringer Ingelheim’s Apecotrep Delivers 40% Proteinuria Reduction in Phase II Primary FSGS Trial

Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive the...

January 29, 2026 | Thursday | News
Roche’s CT-388 Delivers 22.5% Placebo-Adjusted Weight Loss in Phase II Obesity Trial

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at...

January 28, 2026 | Wednesday | News
Longeveron Secures FDA Type C Meeting Ahead of Pivotal ELPIS II Data Readout in HLHS

ELPIS II top-line trial results are anticipated in the third quarter of 2026 Laromestrocel Biological License Application (BLA) submission for full tr...

January 28, 2026 | Wednesday | News
Argo Biopharma and Novartis Dose First Patient in Phase 2b Trial of siRNA Therapy BW-20829

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, announ...

January 27, 2026 | Tuesday | News
BioArctic Partner Eisai Secures FDA Priority Review for Subcutaneous Leqembi Iqlik

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced  that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneo...

January 27, 2026 | Tuesday | News
Scancell Secures FDA IND Clearance for Registrational Phase 3 iSCIB1+ Melanoma Trial

Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard...

January 27, 2026 | Tuesday | News
Alveus Therapeutics Advances ALV-100 Into the Clinic With FDA IND Clearance

Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic d...

January 26, 2026 | Monday | News
BioCryst Completes Acquisition of Astria Therapeutics, Strengthening Leadership in Hereditary Angioedema

BioCryst Pharmaceuticals, Inc.  announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on October 14, 202...

January 26, 2026 | Monday | News
Antibodies Inc. Launches Recombinant Guinea Pig RBPMS Antibody to Advance Retinal Ganglion Cell Research

Antibodies Inc., a leading supplier of validated life science research reagents,  announced the availability of its Recombinant Guinea Pig RBPMS An...

January 23, 2026 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close